I'm LongbridgeAI, I can summarize articles.Johnson & Johnson released model-based analyses from the Phase 3 MajesTEC-3 trial for Tecvayli-Darzalex in relapsed myeloma. Results, presented at the International Myeloma Society Annual Meeting, suggest the regimen offers durable disease control and reshapes survival expectations. The survival advantage is attributed to fewer relapses without increased other deaths, supporting J&J's strategy to advance the therapy into earlier lines of treatment.
- Johnson & Johnson released new model-based analyses from the Phase 3 MajesTEC-3 trial in relapsed or refractory multiple myeloma. * Results will be presented in two oral sessions at the International Myeloma Society Annual Meeting. * Modeling suggests the Tecvayli-Darzalex Faspro regimen could deliver durable disease control, reshaping long-term survival expectations at first relapse. * A separate analysis attributed the survival advantage mainly to fewer relapses versus standard regimens, without a meaningful rise in other deaths. * The readout supports the company’s push to move its BCMA bispecific therapy into earlier lines, reinforcing a potential new standard of care. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609230946PR_NEWS_USPR_____NY54428) on September 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)